Skip to main content
Signal8

Innoviva, Inc. (INVA)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Innoviva, Inc. logo

Innoviva, Inc.

NASDAQ:INVAHealthcare
Pre+0.99%$19.29
Close$19.10-0.73%AH$19.10+0.99%since
Mkt Cap$1.36B
Float68.9M
O/S71.08M
PM VOL279 sh
$ Vol≈$5K
RVOL7.27×
Inst Own-
SI10.6%
Dilution
Innoviva, Inc. logoNASDAQ:INVAPre$19.29+0.99%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 202619.5419.8719.0219.101,654,269
Nov 5, 202620.5920.9119.1919.242,649,747
Nov 4, 202621.2721.5221.0321.26922,346
Nov 3, 202621.0721.3920.9020.93712,646
Nov 2, 202621.2521.6220.8921.021,120,575
Oct 30, 202621.4821.6521.1321.22623,267
Oct 29, 202621.4121.5221.1221.31626,929
Oct 28, 202620.8521.1520.7321.12585,273
Oct 27, 202620.9721.0620.7520.94584,440
Oct 26, 202620.7721.2220.7721.05569,096
Oct 23, 202620.8820.9420.5120.66978,553
Oct 22, 202621.0521.2720.9221.06452,078
Oct 21, 202621.2021.3620.8920.91442,222
Oct 20, 202621.3121.4921.1221.28507,564
Oct 19, 202620.6821.1520.6821.08590,514
Oct 16, 202620.9720.9720.5620.78550,486
Oct 15, 202621.3321.7620.8320.86672,982
Oct 14, 202620.7921.1820.7320.97673,510
Oct 13, 202621.5521.5520.7020.74811,565
Oct 12, 202621.2721.4821.1221.45521,194
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
5
HOLD
4
SELL
1
TOTAL10
Insider Trades
InsiderTypeShares
Raifeld Pavel profile photoRaifeld PavelAutomatic Sell1.1K
Zhen Marianne profile photoZhen MarianneAutomatic Sell1.1K
Basso Stephen profile photoBasso StephenAutomatic Sell558
Raifeld Pavel profile photoRaifeld PavelAutomatic Sell1.1K
Basso Stephen profile photoBasso StephenAutomatic Sell559
Zhen Marianne profile photoZhen MarianneAutomatic Sell1.1K
Shareholders
-
Institutionalⓘ
(307)
1.3%
Insiderⓘ
(8)
3.1%
5%+ Owners
(1)
-
Unattributed (incl. retail)ⓘ
Insider1.3%
5%+ Beneficial3.1%
Sources: 13F, Form 4, 13D/13GO/S: 71.1M · as of 31 Oct 2026 · SEC cover page
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments.

Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA.

The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016.

Its primary operational base is situated in Burlingame, California.

Key Metrics
Market Cap$1.36B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership-

13F filers report 74.45M shares, more than the 71.08M outstanding, so no percentage is shown. 13F reports lag by a quarter and shares lent to short sellers can be counted twice.

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateOct 5, 2004
Shares Outstanding71.08M
Authorized Shares
Float68.90M
52-Week Range
$16.52$25.15
$19.10(30th percentile)
Volume
Average Daily Volume812.46K
1.65M today vs 812.46K avg(+104%)

30d Avg

812.46K

60d Avg

918.37K

90d Avg

819.73K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...